Family Nurse Practitioner (FNP) ANCC &
AANP Exam Bank – OB/GYN + Cardiac
2026 Edition
PART I: THE PRIMER
Mastery of cardiovascular physiology and women’s health separates entry-level practitioners
from elite diagnosticians capable of intercepting catastrophic morbidity. In 2026, relying on
antiquated clinical algorithms constitutes professional negligence; the clinician must anticipate
physiological failure before pathology irreversibly advances.
● The 2026 PREVENT Standard: Initiate pharmacotherapy for Stage 1 Hypertension
(130-139/80-89 mmHg) strictly when the 10-year PREVENT cardiovascular risk score is
≥7.5%.
● Pregnancy HTN (CHAP Protocol): Initiate antihypertensive pharmacotherapy at ≥140/90
mmHg to mitigate severe preeclampsia.
● HRSA Cervical Guidelines: Patient self-collected hrHPV testing is strictly authorized
only for average-risk women aged 30-65.
● Preeclampsia Prophylaxis: Initiate 81mg aspirin between 12-28 weeks (optimally before
16 weeks) for high-risk obstetric profiles.
● Acute PE Disposition: AHA/ACC Category A (subclinical) and Category B (low severity)
mandate early outpatient management utilizing Direct Oral Anticoagulants (DOACs).
PART II: THE ELITE TEST BANK
Q1: Under the 2025/2026 AHA/ACC Hypertension Guidelines, a 45-year-old male presents
with a confirmed blood pressure of 134/84 mmHg. The 10-year PREVENT cardiovascular
risk score is calculated at 8.2%. What is the mandated clinical intervention? A) Initiate a 3-
to 6-month trial of lifestyle modifications alone. B) Initiate blood pressure-lowering medication
alongside lifestyle modifications. C) Order a coronary artery calcium (CAC) score before
prescribing antihypertensives. D) Classify the patient as having Elevated BP and reassess in 6
months.
● The Answer: B (Initiate blood pressure-lowering medication alongside lifestyle
modifications)
● Distractor Analysis: Option A applies strictly to patients with a PREVENT score <7.5%.
Option C delays standard-of-care implementation for a patient already meeting
therapeutic thresholds. Option D relies on obsolete JNC-8 diagnostic criteria; 134/84
mmHg is classified as Stage 1 Hypertension, not Elevated BP.
● The Mentor's Analysis: The 2025/2026 guidelines definitively shifted the primary
prevention threshold. Stage 1 Hypertension requires immediate pharmacological
intervention if the patient's PREVENT score is ≥7.5%. Professional intuition requires the
clinician to recognize that 134/84 mmHg is an actionable pathology when metabolic and
renal factors elevate the PREVENT score above the critical intervention boundary.
Q2: The 2026 HRSA Women’s Preventive Services Guidelines updated the preferred
,cervical cancer screening modality for an average-risk 35-year-old female. Which of the
following aligns with the current primary recommendation? A) Cytology alone every 3
years. B) Co-testing (cytology and hrHPV) every 3 years. C) Primary hrHPV testing every 5
years, which may be self-collected. D) Clinician-collected primary hrHPV testing every 3 years.
● The Answer: C (Primary hrHPV testing every 5 years, which may be self-collected)
● Distractor Analysis: Option A is relegated to settings where hrHPV testing is entirely
unavailable. Option B utilizes the incorrect interval; co-testing is indicated every 5 years.
Option D improperly restricts collection methods and utilizes an outdated 3-year interval
for HPV testing.
● The Mentor's Analysis: HRSA established primary hrHPV testing every 5 years as the
definitive preferred strategy for individuals aged 30-65. The landmark 2026 update
empowers average-risk patients to utilize FDA-approved self-collection devices. This
removes structural barriers to screening while maintaining equivalent diagnostic efficacy
to clinician-collected specimens.
Q3: According to the 2026 AHA/ACC Guidelines for Acute Pulmonary Embolism, an adult
patient diagnosed with a Category A (Subclinical) PE in the emergency department
should be managed via which pathway? A) Admission to a step-down unit for unfractionated
heparin infusion. B) Direct discharge home from the ED without hospitalization. C) Observation
status for 24 hours to monitor right ventricular function. D) Activation of the Pulmonary
Embolism Response Team (PERT) for catheter-directed thrombolysis.
● The Answer: B (Direct discharge home from the ED without hospitalization)
● Distractor Analysis: Options A and C promote over-medicalization, increasing
nosocomial risk and directly violating 2026 guidelines. Option D is strictly reserved for
Category D and E patients exhibiting incipient or actual cardiopulmonary failure.
● The Mentor's Analysis: The AHA/ACC Category A-E framework systematically
de-escalates care for stable patients. Category A represents asymptomatic, subclinical
disease. Guidelines explicitly authorize safe, immediate discharge from the emergency
room without hospitalization, shifting the management paradigm entirely to the outpatient
setting.
Q4: The 2024/2026 USPSTF guidelines for breast cancer screening mandate which of the
following protocols for cisgender women at average risk? A) Annual screening
mammography beginning at age 45. B) Biennial screening mammography beginning at age 40.
C) Individualized shared decision-making for screening between ages 40-49. D) Annual
screening mammography beginning at age 40.
● The Answer: B (Biennial screening mammography beginning at age 40)
● Distractor Analysis: Option A reflects older American Cancer Society parameters.
Option C represents the obsolete pre-2024 USPSTF stance. Option D recommends
annual screening, whereas the USPSTF explicitly calculates the highest net benefit with
biennial intervals.
● The Mentor's Analysis: To mitigate rising mortality in younger
demographics—particularly correcting a 40% higher mortality rate among non-Hispanic
Black women—the USPSTF definitively lowered the universal starting age.
Organization Risk Level Starting Age Frequency
USPSTF (2026) Average 40 Biennial
Q5: A 62-year-old female with Heart Failure with Preserved Ejection Fraction (HFpEF) and
no history of diabetes requires optimization of Guideline-Directed Medical Therapy
(GDMT). Which pharmacological agent is indicated to significantly reduce HF
, hospitalizations? A) Lisinopril B) Metoprolol Succinate C) Empagliflozin D) Digoxin
● The Answer: C (Empagliflozin)
● Distractor Analysis: Options A and B are foundational pillars for HFrEF, lacking robust
primary mortality benefit in HFpEF. Option D provides symptomatic relief in specific
HFrEF/AFib overlap scenarios but exerts zero disease-modifying benefit in HFpEF.
● The Mentor's Analysis: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have
transcended their endocrinologic origins. They serve as the primary disease-modifying
agents for HFpEF, regardless of diabetes status. They induce a nutrient-deprivation
transcriptional state, enhance autophagic flux, and reduce ventricular myofilament
stiffness.
Q6: A 51-year-old menopausal woman seeks relief for severe vasomotor symptoms
(VMS). The patient has a documented history of estrogen-receptor-positive breast cancer.
Which 2025/2026 FDA-approved medication safely targets the hypothalamic
thermoregulatory center without utilizing hormones? A) Conjugated
estrogens/bazedoxifene B) Paroxetine C) Elinzanetant (Lynkuet) D) Estradiol transdermal patch
● The Answer: C (Elinzanetant)
● Distractor Analysis: Options A and D introduce exogenous estrogen, which is absolutely
contraindicated in ER+ breast cancer. Option B is an SSRI utilized off-label for VMS but
does not directly antagonize neurokinin receptors.
● The Mentor's Analysis: Elinzanetant is a pioneering dual NK1 and NK3 receptor
antagonist. Following estrogen depletion, KNDy neurons in the hypothalamus undergo
hypertrophy, hyperactivating the thermoregulatory pathway. Elinzanetant selectively
blocks this mechanism without systemic hormonal exposure, offering a critical modality for
oncology survivors.
Q7: Following ACOG and USPSTF criteria, which pregnant patient definitively qualifies
for prophylactic low-dose aspirin (81mg) to prevent preeclampsia? A) A 22-year-old G1P0
with a BMI of 24 and an unremarkable medical history. B) A 30-year-old G2P1 with a history of
gestational diabetes, currently normoglycemic. C) A 28-year-old G1P0 with systemic lupus
erythematosus (SLE). D) A 35-year-old G3P2 with a history of uncomplicated vaginal deliveries.
● The Answer: C (A 28-year-old G1P0 with systemic lupus erythematosus)
● Distractor Analysis: Option A presents a low-risk profile. Option B features a single
moderate-risk factor; prophylaxis requires at least two moderate factors. Option D
represents advanced maternal age, functioning as a solitary moderate-risk factor.
● The Mentor's Analysis: Autoimmune diseases (SLE, antiphospholipid syndrome)
operate as standalone, high-risk criteria for preeclampsia, mandating the initiation of
81mg aspirin between 12-28 weeks gestation. Endothelial dysfunction drives
preeclampsia pathophysiology; aspirin administration fundamentally mitigates aberrant
platelet aggregation and placental vasoconstriction.
Q8: The CDC's 2025/2026 STI treatment guidelines formally endorse Doxy-PEP for which
specific epidemiological cohort? A) All sexually active cisgender females under age 25. B)
Pregnant women with a documented history of syphilis. C) Men who have sex with men (MSM)
and transgender women with a bacterial STI history in the past 12 months. D) Any individual
actively utilizing HIV Pre-Exposure Prophylaxis (PrEP).
● The Answer: C (Men who have sex with men and transgender women with a bacterial
STI history in the past 12 months)
● Distractor Analysis: Option A lacks clinical efficacy data. Option B constitutes a
catastrophic error; doxycycline induces fetal tooth discoloration and is strictly
contraindicated in pregnancy. Option D applies the intervention too broadly without regard
AANP Exam Bank – OB/GYN + Cardiac
2026 Edition
PART I: THE PRIMER
Mastery of cardiovascular physiology and women’s health separates entry-level practitioners
from elite diagnosticians capable of intercepting catastrophic morbidity. In 2026, relying on
antiquated clinical algorithms constitutes professional negligence; the clinician must anticipate
physiological failure before pathology irreversibly advances.
● The 2026 PREVENT Standard: Initiate pharmacotherapy for Stage 1 Hypertension
(130-139/80-89 mmHg) strictly when the 10-year PREVENT cardiovascular risk score is
≥7.5%.
● Pregnancy HTN (CHAP Protocol): Initiate antihypertensive pharmacotherapy at ≥140/90
mmHg to mitigate severe preeclampsia.
● HRSA Cervical Guidelines: Patient self-collected hrHPV testing is strictly authorized
only for average-risk women aged 30-65.
● Preeclampsia Prophylaxis: Initiate 81mg aspirin between 12-28 weeks (optimally before
16 weeks) for high-risk obstetric profiles.
● Acute PE Disposition: AHA/ACC Category A (subclinical) and Category B (low severity)
mandate early outpatient management utilizing Direct Oral Anticoagulants (DOACs).
PART II: THE ELITE TEST BANK
Q1: Under the 2025/2026 AHA/ACC Hypertension Guidelines, a 45-year-old male presents
with a confirmed blood pressure of 134/84 mmHg. The 10-year PREVENT cardiovascular
risk score is calculated at 8.2%. What is the mandated clinical intervention? A) Initiate a 3-
to 6-month trial of lifestyle modifications alone. B) Initiate blood pressure-lowering medication
alongside lifestyle modifications. C) Order a coronary artery calcium (CAC) score before
prescribing antihypertensives. D) Classify the patient as having Elevated BP and reassess in 6
months.
● The Answer: B (Initiate blood pressure-lowering medication alongside lifestyle
modifications)
● Distractor Analysis: Option A applies strictly to patients with a PREVENT score <7.5%.
Option C delays standard-of-care implementation for a patient already meeting
therapeutic thresholds. Option D relies on obsolete JNC-8 diagnostic criteria; 134/84
mmHg is classified as Stage 1 Hypertension, not Elevated BP.
● The Mentor's Analysis: The 2025/2026 guidelines definitively shifted the primary
prevention threshold. Stage 1 Hypertension requires immediate pharmacological
intervention if the patient's PREVENT score is ≥7.5%. Professional intuition requires the
clinician to recognize that 134/84 mmHg is an actionable pathology when metabolic and
renal factors elevate the PREVENT score above the critical intervention boundary.
Q2: The 2026 HRSA Women’s Preventive Services Guidelines updated the preferred
,cervical cancer screening modality for an average-risk 35-year-old female. Which of the
following aligns with the current primary recommendation? A) Cytology alone every 3
years. B) Co-testing (cytology and hrHPV) every 3 years. C) Primary hrHPV testing every 5
years, which may be self-collected. D) Clinician-collected primary hrHPV testing every 3 years.
● The Answer: C (Primary hrHPV testing every 5 years, which may be self-collected)
● Distractor Analysis: Option A is relegated to settings where hrHPV testing is entirely
unavailable. Option B utilizes the incorrect interval; co-testing is indicated every 5 years.
Option D improperly restricts collection methods and utilizes an outdated 3-year interval
for HPV testing.
● The Mentor's Analysis: HRSA established primary hrHPV testing every 5 years as the
definitive preferred strategy for individuals aged 30-65. The landmark 2026 update
empowers average-risk patients to utilize FDA-approved self-collection devices. This
removes structural barriers to screening while maintaining equivalent diagnostic efficacy
to clinician-collected specimens.
Q3: According to the 2026 AHA/ACC Guidelines for Acute Pulmonary Embolism, an adult
patient diagnosed with a Category A (Subclinical) PE in the emergency department
should be managed via which pathway? A) Admission to a step-down unit for unfractionated
heparin infusion. B) Direct discharge home from the ED without hospitalization. C) Observation
status for 24 hours to monitor right ventricular function. D) Activation of the Pulmonary
Embolism Response Team (PERT) for catheter-directed thrombolysis.
● The Answer: B (Direct discharge home from the ED without hospitalization)
● Distractor Analysis: Options A and C promote over-medicalization, increasing
nosocomial risk and directly violating 2026 guidelines. Option D is strictly reserved for
Category D and E patients exhibiting incipient or actual cardiopulmonary failure.
● The Mentor's Analysis: The AHA/ACC Category A-E framework systematically
de-escalates care for stable patients. Category A represents asymptomatic, subclinical
disease. Guidelines explicitly authorize safe, immediate discharge from the emergency
room without hospitalization, shifting the management paradigm entirely to the outpatient
setting.
Q4: The 2024/2026 USPSTF guidelines for breast cancer screening mandate which of the
following protocols for cisgender women at average risk? A) Annual screening
mammography beginning at age 45. B) Biennial screening mammography beginning at age 40.
C) Individualized shared decision-making for screening between ages 40-49. D) Annual
screening mammography beginning at age 40.
● The Answer: B (Biennial screening mammography beginning at age 40)
● Distractor Analysis: Option A reflects older American Cancer Society parameters.
Option C represents the obsolete pre-2024 USPSTF stance. Option D recommends
annual screening, whereas the USPSTF explicitly calculates the highest net benefit with
biennial intervals.
● The Mentor's Analysis: To mitigate rising mortality in younger
demographics—particularly correcting a 40% higher mortality rate among non-Hispanic
Black women—the USPSTF definitively lowered the universal starting age.
Organization Risk Level Starting Age Frequency
USPSTF (2026) Average 40 Biennial
Q5: A 62-year-old female with Heart Failure with Preserved Ejection Fraction (HFpEF) and
no history of diabetes requires optimization of Guideline-Directed Medical Therapy
(GDMT). Which pharmacological agent is indicated to significantly reduce HF
, hospitalizations? A) Lisinopril B) Metoprolol Succinate C) Empagliflozin D) Digoxin
● The Answer: C (Empagliflozin)
● Distractor Analysis: Options A and B are foundational pillars for HFrEF, lacking robust
primary mortality benefit in HFpEF. Option D provides symptomatic relief in specific
HFrEF/AFib overlap scenarios but exerts zero disease-modifying benefit in HFpEF.
● The Mentor's Analysis: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have
transcended their endocrinologic origins. They serve as the primary disease-modifying
agents for HFpEF, regardless of diabetes status. They induce a nutrient-deprivation
transcriptional state, enhance autophagic flux, and reduce ventricular myofilament
stiffness.
Q6: A 51-year-old menopausal woman seeks relief for severe vasomotor symptoms
(VMS). The patient has a documented history of estrogen-receptor-positive breast cancer.
Which 2025/2026 FDA-approved medication safely targets the hypothalamic
thermoregulatory center without utilizing hormones? A) Conjugated
estrogens/bazedoxifene B) Paroxetine C) Elinzanetant (Lynkuet) D) Estradiol transdermal patch
● The Answer: C (Elinzanetant)
● Distractor Analysis: Options A and D introduce exogenous estrogen, which is absolutely
contraindicated in ER+ breast cancer. Option B is an SSRI utilized off-label for VMS but
does not directly antagonize neurokinin receptors.
● The Mentor's Analysis: Elinzanetant is a pioneering dual NK1 and NK3 receptor
antagonist. Following estrogen depletion, KNDy neurons in the hypothalamus undergo
hypertrophy, hyperactivating the thermoregulatory pathway. Elinzanetant selectively
blocks this mechanism without systemic hormonal exposure, offering a critical modality for
oncology survivors.
Q7: Following ACOG and USPSTF criteria, which pregnant patient definitively qualifies
for prophylactic low-dose aspirin (81mg) to prevent preeclampsia? A) A 22-year-old G1P0
with a BMI of 24 and an unremarkable medical history. B) A 30-year-old G2P1 with a history of
gestational diabetes, currently normoglycemic. C) A 28-year-old G1P0 with systemic lupus
erythematosus (SLE). D) A 35-year-old G3P2 with a history of uncomplicated vaginal deliveries.
● The Answer: C (A 28-year-old G1P0 with systemic lupus erythematosus)
● Distractor Analysis: Option A presents a low-risk profile. Option B features a single
moderate-risk factor; prophylaxis requires at least two moderate factors. Option D
represents advanced maternal age, functioning as a solitary moderate-risk factor.
● The Mentor's Analysis: Autoimmune diseases (SLE, antiphospholipid syndrome)
operate as standalone, high-risk criteria for preeclampsia, mandating the initiation of
81mg aspirin between 12-28 weeks gestation. Endothelial dysfunction drives
preeclampsia pathophysiology; aspirin administration fundamentally mitigates aberrant
platelet aggregation and placental vasoconstriction.
Q8: The CDC's 2025/2026 STI treatment guidelines formally endorse Doxy-PEP for which
specific epidemiological cohort? A) All sexually active cisgender females under age 25. B)
Pregnant women with a documented history of syphilis. C) Men who have sex with men (MSM)
and transgender women with a bacterial STI history in the past 12 months. D) Any individual
actively utilizing HIV Pre-Exposure Prophylaxis (PrEP).
● The Answer: C (Men who have sex with men and transgender women with a bacterial
STI history in the past 12 months)
● Distractor Analysis: Option A lacks clinical efficacy data. Option B constitutes a
catastrophic error; doxycycline induces fetal tooth discoloration and is strictly
contraindicated in pregnancy. Option D applies the intervention too broadly without regard
